Clinical Transfers®: State-of-the-Art Management for NSCLC: Novel Targets and Therapies

Program Overview

The landscape of precision medicine for non-small cell lung cancer (NSCLC) is continually evolving with an ever-expanding armamentarium of targeted agents. This educational activity is designed to provide a synopsis of novel targets and therapies. Jacob Sands, MD, a thoracic medical oncologist, will provide the latest data for newly approved and investigational MET and RET inhibitors, as well as the latest evidence for drug-antibody conjugates directed towards HER2, HER3, TROP2, and B7-H3.

Credit Expired
CE Credit Expired
Expires: July 30, 2021

Target Audience

This activity is designed to meet the educational needs of oncology and pathology clinicians involved in the treatment of patients with non-small cell lung cancer (NSCLC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Assess the potential role of novel therapies directed against TROP2 and other emerging targets in the management of non-small cell lung cancer (NSCLC)
  • Identify the potential impact of HER2-/3-directed therapies on the current NSCLC treatment algorithm

Activity Faculty

Jacob Sands, MD 
Photo by Sam Ogden

Jacob Sands, MD

Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Supporter Statement

Provider Statement

Disclosure of Financial Relationships

Faculty

Planners and Managers

Method of Participation and Request for Credit

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2024. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | www.RMEI.com | (866) 770-RMEI

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources